Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy
Recently, many combination therapies involving an immune checkpoint inhibitor targeting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway and another treatment option such as chemotherapy, radiation therapy, and various immunotherapy agents have been explored to improve the response rate and clinical outcomes in various solid tumors including non-small cell lung cancer (NSCLC) [1 –8]. Especially, combination therapy with an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor and a PD-1/PD-L1 inhibitor is expected to be a novel and effective treatment option and is currently attracting a lot of attention.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Kazuki Takada, Kenichi Kohashi, Mototsugu Shimokawa, Akira Haro, Atsushi Osoegawa, Tetsuzo Tagawa, Takashi Seto, Yoshinao Oda, Yoshihiko Maehara Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Radiation Therapy | Skin Cancer | Squamous Cell Carcinoma